Roser M, Ritchie H, Spooner F (2017) Burden of Disease. Available from: https://ourworldindata.org/burden-of-disease.

Bueno H, Camm AJ, Lüscher TF, Maurer G, Serruys PW (2018) Epidemiology of acute coronary syndromes. In: James S (ed) The ESC textbook of cardiovascular medicine. Oxford University Press, Oxford

Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al (2019) ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140(11):e596–e646

PubMed  PubMed Central  Google Scholar 

Timmis A, Kazakiewicz D, Townsend N, Huculeci R, Aboyans V, Vardas P (2023) Global epidemiology of acute coronary syndromes. Nat Rev Cardiol 20(11):778–788

Article  PubMed  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2019) ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother 41(1):111–188

Google Scholar 

Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR (2018) Appropriateness of statin prescription in the elderly. Eur J Intern Med 50:33–40

Article  CAS  PubMed  Google Scholar 

Sigglekow F, Horsburgh S, Parkin L (2020) Statin adherence is lower in primary than secondary prevention: a national follow-up study of new users. PLoS ONE 15(11):e0242424

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D et al (2021) High-intensity statins benefit high-risk patients: why and how to do better. Mayo Clin Proc 96(10):2660–2670

Article  PubMed  Google Scholar 

Kim J, Park KT, Jang MJ, Park TK, Lee JM, Yang JH et al (2018) High-intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention. J Am Heart Assoc 7(21):e009517

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H et al (2015) Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol 65(3):270–277

Article  PubMed  Google Scholar 

Lee SJ, Kang WC, Lee JY, Lee JB, Yang TH, Yoon J et al (2023) Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial. EClinicalMedicine 64:102227

Article  PubMed  PubMed Central  Google Scholar 

Indonesian Health Minister (2016) Peraturan Menteri Kesehatan No.64 Tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Program Jaminan Kesehatan [Minister of Health Regulation No. 64 Concerning Standard Health Service Tariffs in the Implementation of Health Insurance Programs]. Jakarta: Indonesian Ministry of Health

Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ (2020) Perspective and costing in cost-effectiveness analysis, 1974–2018. Pharmacoeconomics 38(10):1135–1145

Article  PubMed  PubMed Central  Google Scholar 

Abbott JH, Wilson R, Pryymachenko Y et al (2022) Economic evaluation: a reader’s guide to studies of cost-effectiveness. Arch Physiother 12(28)

Neumann PJ (2009) Costing and perspective in published cost-effectiveness analysis. Med Care 47(7):S28–S32

Article  PubMed  Google Scholar 

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med 20(1):23

Article  PubMed  PubMed Central  Google Scholar 

Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S (2011) Applied methods of cost-effectiveness analysis in healthcare. Oxford University Press

Google Scholar 

Gidwani R, Russell LB (2020) Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics 38(11):1153–1164

Article  PubMed  PubMed Central  Google Scholar 

Taylor DC, Pandya A, Thompson D, Chu P, Graff J, Shepherd J et al (2009) Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ 10(3):255–265

Article  PubMed  Google Scholar 

Lin FJ, Shyu KG, Hsieh IC, Huey-Herng Sheu W, Tu ST, Yeh SJ, Chen CI, Lu KC, Wu CC, Shau WY, Inocencio TJ, Wen YC, Yeh HI (2020) Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan. J Formos Med Assoc 119(5):907–916. https://doi.org/10.1016/j.jfma.2020.01.010

Article  CAS  PubMed  Google Scholar 

Barrios V, Kaskens L, Castellano JM, Cosin-Sales J, Ruiz JE, Zsolt I et al (2017) Usefulness of a cardiovascular polypill in the treatment of secondary prevention patients in Spain: a cost-effectiveness study. Rev Esp Cardiol 70(1):42–49

Article  PubMed  Google Scholar 

Almalki ZS, Guo JJ, Alahmari A, Alotaibi N, Thaibah H (2018) Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in patients with a history of acute coronary syndrome: analysis of results of the IMPROVE-IT trial. Heart Lung Circ 27(6):656–665

Article  PubMed  Google Scholar 

Gómez-Gerique JA, Casciano R, Stern L, Rejas J (2004) A pharmacoeconomic evaluation of the of the effects of atorvastatin on early recurrent coronary syndromes in Spain. Eur J Health Econ 5(3):278–284

Article  PubMed  Google Scholar 

Ademi Z, Reid CM, Hollingsworth B, Stoelwinder J, Steg PG, Bhatt DL et al (2011) Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry. Clin Ther 33(10):1456–1465

Article  PubMed  Google Scholar 

Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L (2011) Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124(2):146–153

Article  CAS  PubMed  Google Scholar 

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S (2007) Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 115(18):2398–2409

Article  PubMed  Google Scholar 

Rockberg J, Jørgensen L, Taylor B, Sobocki P, Johansson G (2017) Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment. Prev Med Rep 6:203–209

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S (2015) Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 93(2):118–124

Article  PubMed  Google Scholar 

Kristina SA, Endarti D, Wiedyaningsih C, Fahamsya A, Faizah N (2018) Health care cost of noncommunicable diseases related to smoking in Indonesia, 2015. Asia Pac J Public Health 30(1):29–35

Article  PubMed  Google Scholar 

Andayani TM, Endarti D, Kristina SA, Rokhman MR (2017) Metode Untuk Memperkirakan Willingness-To-Pay per Quality Adjusted Life Year Sebagai Cost-Effectiveness Threshold [Methods for Estimating Willingness-To-Pay per Quality Adjusted Life Year as a Cost-Effectiveness Threshold]. Jur Manaj Pelay Farm 7:142–147

Google Scholar 

Kytö V, Rautava P, Tornio A (2023) Initial statin dose after myocardial infarction and long-term cardiovascular outcomes. Eur Heart J Cardiovasc Pharmacother 9(2):156–164

Article  PubMed  Google Scholar 

Xie G, Myint PK, Sun Y, Li X, Wu T, Gao RL et al (2022) Associated factors for discontinuation of statin use one year after discharge in patients with acute coronary syndrome in China. BMJ Open 12(9):e056236

Article  PubMed  PubMed Central  Google Scholar 

Desjobert E, Tea V, Schiele F, Ferrières J, Simon T, Danchin N et al (2021) Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: the FAST-MI registries. Arch Cardiovasc Dis 114(2):88–95

Article  PubMed  Google Scholar 

Castillo-Costa YB, Mauro VM, Charask AA, Fairman E, Buhezo H, Barrero C (2018) Use of high-intensity statin strategy. Are the guidelines followed? Revista Argentina de Cardiologia 86(1):45–47

Article  Google Scholar 

Diaz R, Li QH, Bhatt DL et al (2020) Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol 0(0)

Sulzgruber P, Sinkovec H, Kazem N, Hofer F, Hammer A, Koller L, Todorovic M, Katsch F, Gall W, Duftschmid G, Heinze G, Niessner A (2020) Adherence to high-intensity statin therapy after acute coronary syndrome and its impact on patient outcome. Eur Heart J 41(2)

Husain MJ, Spencer G, Nugent R, Kostova D, Richter P (2022) The cost-effectiveness of hyperlipidemia medication in low- and middle-income countries: a review. Glob Heart 17(1):18

Article  PubMed  PubMed Central  Google Scholar 

Nherera L, Calvert NW, Demott K, Humphries SE, Neil HA, Minhas R, Thorogood M (2010) Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 26(3):529–536

Article  CAS  PubMed  Google Scholar